DZ Bank Call 2.8488 MDGD 20.12.20.../ DE000DW83PB5 /
6/24/2024 6:35:00 PM | Chg.0.000 | Bid6/24/2024 | Ask- | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.001EUR | 0.00% | 0.001 Bid Size: 3,500 |
- Ask Size: - |
MEDIGENE AG NA O.N. | 2.8488 EUR | 12/20/2024 | Call |
GlobeNewswire
6/20
Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumor...
GlobeNewswire
5/28
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology ...
GlobeNewswire
5/21
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announ...
GlobeNewswire
5/15
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
GlobeNewswire
5/14
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
GlobeNewswire
5/6
The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conferenc...
GlobeNewswire
5/2
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell R...
GlobeNewswire
5/2
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
GlobeNewswire
4/25
Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
GlobeNewswire
4/8
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR ...
GlobeNewswire
3/28
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
3/19
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
GlobeNewswire
3/6
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Pr...
GlobeNewswire
3/4
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety...